ReviewMolecular biology reports2026
In silico analysis of selected polyphenols as potential multitarget rheumatoid arthritis modifying agents.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRheumatoid arthritis (RA) arises from a complex inflammatory network involving cytokines, kinases, and matrix degrading enzymes. Methotrexate is the clinical standard but is limited by poor pharmacokinetics and a narrow mechanism. METHODOLOGY: This study evaluates six polyphenols sinapic acid, catechin, galangin, piceatannol, umbelliferone, and pinocembrin against fifteen validated RA targets and benchmarks them against methotrexate.An integrated in silico framework assessed ADME properties, molecular docking, and network pharmacology. ADME screening included Lipinski compliance, GI absorption, solubility, CYP450, and bioavailability.
resultsAll polyphenols fullfill Lipinski’s criteria and showed moderate lipophilicity, high predicted GI absorption, favourable solubility, minimal CYP450 interactions, and bioavailability scores of 0.55. Methotrexate displayed one rule violation, extreme hydrophilicity, poor permeability, low GI absorption, and a bioavailability score of 0.11. Docking confirmed methotrexate as the strongest single-target binder; however, catechin, piceatannol, galangin, and umbelliferone demonstrated strong affinities (–6.1 to –9.9 kcal/mol), particularly to iNOS, COX-2, and MMP-9. Network analysis highlighted modulation of TNF, IL-17, JAK–STAT, NF-κB, RA, and arachidonic-acid pathways and GO linked to inflammation and matrix degradation.
conclusionThe polyphenols, in combination with catechin, are pharmacokinetically robust multitarget modulators capable of suppressing cytokine signalling, kinase activation, NF-κB transcription, and matrix degradation, therefore positing these phytochemicals as promising for next-generation RA therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.